Bevacizumab in the Treatment of Glioblastoma: Is There an Optimal Dose or Schedule?

doi 10.2174/978160805132811001010054
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BENTHAM SCIENCE PUBLISHERS

Related search

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Prophylactic Nitrate Therapy in Angina Pectoris-Is There an Optimal Treatment Regimen?

British Journal of Clinical Pharmacology
Pharmacology
1992English

Is There Optimal Behavioral Treatment Intensity for Dysphagia?

International Journal of Clinical & Experimental Otolaryngology
2015English

Efficacy and Safety of Bevacizumab for the Treatment of Glioblastoma

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2015English

Is There an Optimal Industry Financial Structure?

2002English

Update and Developments in the Treatment of Glioblastoma Multiforme &Ndash; Focus on Bevacizumab

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2010English

IP Restoration vs. WDM Protection: Is There an Optimal Choice?

IEEE Network
Information SystemsComputer NetworksHardwareCommunicationsArchitectureSoftware
2000English

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Single Dose Bevacizumab as Treatment for Symptomatic, Corticosteroid-Refractory Pseudoprogression After Chemoradiation Therapy for Newly Diagnosed Glioblastoma: A Case Report

Integrative Cancer Science and Therapeutics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy